Visterra, Inc. IPO Advisory
Share this IPO Profile:
Smart Search
For IPO Boutique's "scale of 1 to 5" BUY rating on Visterra, Inc., and our comprehensive analysis, click "
Buy Market Research".
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
Visterra, Inc. | VIST - NASDAQ |
$12.00-$14.00 |
$0.00 |
$0.00 | 3.9 million | |
Leerink Partners, Stifel |
Co-Manager(s): Needham & Company, Wedbush PacGrow |
Health Care |
Filing(s): Filed 2016-01-05 Terms Added 2017-01-17
|
About Visterra, Inc. (adapted from Visterra, Inc. prospectus):
They are a clinical-stage biopharmaceutical company focused on applying their novel Hierotope platform to identify unique disease targets and to design and engineer innovative antibody-based therapies that are intended to be effective as a single-dose administration.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "VIST" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
© 2005 - 2025 IPO Boutique. All Rights Reserved